Ensifentrine
- Generic Name
- Ensifentrine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H31N5O4
- CAS Number
- 1884461-72-6
- Unique Ingredient Identifier
- 3E3D8T1GIX
- Background
Ensifentrine is under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD).
- Associated Conditions
- -
- Associated Therapies
- -
DirectRx pharmacy distributing COPD therapy Ohtuvayre in US
DirectRx, a specialty pharmacy, is now part of the exclusive U.S. network distributing Ohtuvayre (ensifentrine), a newly approved COPD therapy. Ohtuvayre, priced at $2,950 per month, is the first new COPD therapy in over two decades, offering both anti-inflammatory and airway-widening effects without the side effects of inhaled corticosteroids. It was approved based on Phase 3 trial data showing significant improvements in lung function and reduced exacerbation rates.
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs
GSK's MATINEE Phase 3 trial showed Nucala (mepolizumab) significantly reduced COPD exacerbations in type 2 inflammation patients, with safety consistent with known profile. Nucala is not yet indicated for COPD but contributed 6% to GSK's 2023 sales.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath